A 2026 study in the Journal of Endocrinological Investigation paired a cross-sectional analysis with a randomized controlled trial to ask whether vitamin D changes fatty liver - and the answer is a careful yes. In adults with overweight or obesity and MASLD, a weekly vitamin D dose reduced liver fat more than lifestyle change alone, over 24 weeks. The caveat, and it is a real one, is that the same study did not move liver stiffness, the marker of scarring.
The study is worth reading slowly because it lands exactly where most supplement stories do: a real effect on the reversible part (fat), and no clear effect on the harder part (fibrosis). That is the honest shape of the finding, and it is the reason the dose matters - the trial used 14,000 IU per week, roughly 2,000 IU a day, which is a high dose that belongs under a clinician’s watch, not a bottle to self-prescribe.
What the trial actually did
The randomized part compared vitamin D supplementation against lifestyle change alone, and the headline is that the supplement group lost more liver fat. The cross-sectional part set the table for it: vitamin D deficiency tracks with worse MASLD in the first place, so a trial that corrects the deficiency is asking whether the association is reversible. The 24-week result says the fat part is, at least partly.
The stiffness result is the part that keeps the story honest. Liver stiffness is the noninvasive stand-in for fibrosis, and the supplement did not move it. That means vitamin D looks like it helps prevent or reduce fat accumulation, but it is not evidence that it reverses existing scarring - which is exactly why early intervention matters and why the supplement does not replace the lifestyle changes that drive the fat reduction.
Where the plate still sits
A supplement trial is not a license to skip the plate - it is a reminder that the plate is still the primary tool and the supplement is a possible add-on for a measured deficiency. The Recommended column - salmon, legumes, whole grains, olive oil, vegetables - is the pattern that drives liver-fat loss through the food itself, and vitamin D is the correction for a specific deficiency, not a substitute for that pattern.
The food sources deserve a mention because vitamin D is one of the few nutrients the database does not rate directly, and the fatty fish that carry it are already in the Recommended column. Salmon sits around 1.3 grams of saturated fat per 100 grams with omega-3s and some vitamin D; the point is that the food and the supplement are pulling the same lever, and the food is the part a reader controls without a dose question.
How our editorial team read this
We read supplement trials with a standing rule: report the effect, keep the dose behind a clinician, and never let a single study turn into a bottle recommendation. Our data editor verified the study, the dose, and the stiffness null result, and we kept the framing on the fat-versus-fibrosis split that makes the finding honest. We did not say the supplement cures fatty liver, and we did not name a dose a reader should take on their own.
What we did do is keep the supplement in its place - a possible correction for a measured deficiency, added to a pattern the reader already controls. The reader-facing line is simple: check the level if a clinician suggests it, treat the deficiency if one is found, and keep the plate as the primary tool either way.
The practical takeaway
For someone with MASLD, the vitamin D trial is a reason to ask about a level check, not to self-prescribe. The plate remains the primary lever, the supplement is a clinician-supervised add-on for a measured deficiency, and the honest finding is that the fat responds while the scarring is a different, harder question.